Highlights of This Issue 3097

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3099  CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla
Patrick Hwu

CCR Translations

3102  Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo
See related article, p. 3140

3105  Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Manmeet S. Ahluwalia and Jeremy N. Rich
See related article, p. 3307

Molecular Pathways

3108  Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

Reviews

3113  Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121  Nanotechnology: Future of Oncotherapy
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

CANCER THERAPY: CLINICAL

3131  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Muriel Hannon, Yves Béguein, Grégoire Ehx, Sophie Servais, Laurence Seidel, Carlos Graux, Johan Maertens, Tessa Kerre, Coline Daunle, Muriel de Bock, Marianne Fillef, Aurélie Ory, Evelyne Willems, André Gothot, Stéphanie Humbert-Baron, and Frédéric Baron

3140  PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Redford, Peter Hersey, Georgina V. Long, and Richard A. Scoller
See related commentary, p. 3102

3149  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz, Rachel A. Burga, Elise McCormack, Li Juan Wang, Wesley Mooring, Gary R. Point, Pranay D. Khare, Mitchell Thorn, Qiangzhong Ma, Brian F. Stainken, Earle O. Assanah, Robin Davies, N. Joseph Espat, and Richard J. Junghans

3150  Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Faramsh T. Awan

3170  Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3187  Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Victor Strojan, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meliin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu
Table of Contents

3327  Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

3340  Genetic Modulation of Neurocognitive Function in Glioma Patients
Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

3347  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

CORRECTIONS

3356  Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

3358  Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

3359  Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

ABOUT THE COVER

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.